Hyasynthbio is developing a method to produce cannabinoids using yeast through industrial fermentation, aiming to provide a more scalable, efficient, and sustainable alternative to traditional chemical synthesis or cannabis cultivation. This approach addresses the growing demand for cannabinoids, which are used to treat conditions like epilepsy and chronic pain, and can help reduce opioid use.

The co-founders, experts in yeast genetic engineering, have created yeast strains that produce cannabinoids at a large scale. Their method leverages industrial fermentation, a widely used and established manufacturing process in food and pharmaceuticals. This innovation promises to deliver cannabinoids that are rare or novel, potentially enhancing therapeutic options.

Hyasynthbio has partnered with major companies such as Organigram to commercialize their products and is working to establish global connections with researchers and companies aligned with their mission. Their goal is to create a reliable and sustainable supply chain for these unique cannabinoid products.

“Our aim is to make a sustainable and reliable supply chain for these unique products.” – Hyasynth Team 

‍